Date: 27-Aug-2019

First patient dosed for Phase I/II trial of avapritinib in advanced GIST

CStone Pharmaceuticals, on 26 August 2019, announced that the first patient in China has been dosed in Phase I/II bridging the study of avapritinib, which was discovered by CStones partner Blueprint Medicines. This stand-alone registrational bridging study in China includes a Phase I dose-escalation study and Phase II dose-expansion study, with the aim of evaluating the safety, pharmacokinetics and efficacy of avapritinib in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). This study consists of patients with PDGFRA D842V-driven GIST, as well as second- and third-line or later GIST patients.